-+ 0.00%
-+ 0.00%
-+ 0.00%

Nasus Pharma To Present Topline Analysis From Its Phase 2 Repeated Dose Clinical Study Of NS002

Benzinga·03/09/2026 12:34:05
Listen to the news

Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of the Company's management will host a conference call and webcast on Monday, March 16, 2026, at 8:00 a.m. ET to present and discuss the topline analysis from the Phase 2 repeated dose clinical study of NS002, the Company's intranasal powder epinephrine product candidate. A question-and-answer session will follow the data presentation.